Catalog Products » CLEC4A/DCIR hFc Chimera, Human
Manual
Manual
COAs

CLEC4A/DCIR hFc Chimera, Human

Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
$340.00
Z05177-100

Ask us a question
Product Introduction
Species Human
Protein Construction
CLEC4A/DCIR (Gln70-Leu237)
Accession # Q9UMR7-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 46.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CLEC4A/DCIR HFc Chimera, Human

Immobilized CLEC4A/DCIR hFc Chimera, Human, hFc Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-CLEC4A Antibody, hFc Tag with the EC50 of 29.8ng/ml determined by ELISA. »

CLEC4A/DCIR HFc Chimera, Human

The purity of CLEC4A/DCIR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

CLEC4A/DCIR HFc Chimera, Human

CLEC4A/DCIR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
Synonyms CD367; Clec4a2; CLECSF6; DCIR; DDB27; HDCGC13P; LLIR; CLEC4A; DCIRLLIR
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.